Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta

被引：0

作者：

Lampertico, Pietro ^{[1
,2
]}

Aleman, Soo ^{[3
]}

Blank, Antje ^{[4
]}

Bogomolov, Pavel ^{[5
]}

Chulanov, Vladimir ^{[6
]}

Mamonova, Nina ^{[6
]}

Viacheslav, Morozov ^{[7
]}

Sagalova, Olga ^{[8
]}

Stepanova, Tatyana ^{[9
]}

Suri, Vithika ^{[10
]}

Manuilov, Dmitry ^{[10
]}

Ye, Lei ^{[10
]}

Flaherty, John F. ^{[10
]}

Osinusi, Anu ^{[10
]}

Cornberg, Markus ^{[11
]}

Brunetto, Maurizia ^{[12
,13
]}

Wedemeyer, Heiner ^{[11
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Gastroenterol & Hepatol, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, CRC AM & A Migliavacca Ctr Liver Dis, Milan, Italy

[3] Karolinska Univ Hosp, Dept Infect Dis, Karolinska Inst, Stockholm, Sweden

[4] Univ Heidelberg Hosp, Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany

[5] Moscow Reg Res clin Inst, State budgetary Inst Hlth care Moscow reg, Moscow, Russia

[6] Minist Hlth Russian Federat, FSBI Natl Res Med Ctr Phthisiopulmonol & Infect D, Moscow, Russia

[7] LLC Med Co Hepatol, Samara, Russia

[8] Southern Ural State Mad Univ, Federal state funded Inst higher Educ, Minist Hlth Russian, Chelyabinsk, Russia

[9] Ltd Iiabil Co Clin Modern Med, Moscow, Russia

[10] Gilead Sci, Foster City, CA USA

[11] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, Hannover, Germany

[12] Univ Hosp Pisa, Hepatol Unit, Reference Ctr, Tuscany Reg Chron Liver Dis & Canc, Pisa, Italy

[13] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

来源：

JOURNAL OF HEPATOLOGY | 2022年 / 77卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT351

引用

页码：S828 / S828

页数：1

共 50 条

[1] Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta
Lampertico, Pietro
Aleman, Soo
Asselah, Tarik
Bourliere, Marc
Streinu-Cercel, Adrian
Bogomolov, Pavel
Viacheslav, Morozov
Stepanova, Tatyana
Lazar, Stefan
Suri, Vithika
Manuilov, Dmitry
Ye, Lei
Flaherty, John F.
Osinusi, Anu
Brunetto, Maurizia
Wedemeyer, Heiner
JOURNAL OF HEPATOLOGY, 2022, 77 : S829 - S829
[2] EFFICACY AND SAFETY OF BULEVIRTIDE MONOTHERAPY GIVEN AT 2 MG OR 10 MG DOSE LEVEL ONCE DAILY FOR TREATMENT OF CHRONIC HEPATITIS DELTA: WEEK 48 PRIMARY ENDPOINT RESULTS FROM A PHASE 3 RANDOMIZED, MULTICENTER, PARALLEL-DESIGN STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Shah, Vicki
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2023, 164 (06) : S1367 - S1368
[3] Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
Zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2022, 77 : S4 - S5
[4] Efficacy and safety of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis delta at 96 weeks: Results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Freismuth, Aurelie
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 101 - 102
[5] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 (SUPPL_3) : A103 - A104
[6] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia R.
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana V.
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey H.
Wiesch, Julian Schulze zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GASTROENTEROLOGY, 2024, 166 (05) : S1600 - S1600
[7] EFFICACY AND SAFETY AT 96 WEEKS OF BULEVIRTIDE 2 MG OR 10 MG MONOTHERAPY FOR CHRONIC HEPATITIS DELTA: RESULTS FROM AN INTERIM ANALYSIS OF A PHASE 3 RANDOMIZED STUDY
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John
Osinusi, Anu
Lau, Audrey
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
GUT, 2023, 72 : A103 - A104
[8] Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study
Lee, Stacey
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Morozov, Viacheslav
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Suri, Vithika
An, Qi
Flaherty, John F.
Osinusi, Anu
zur Wiesch, Julian Schulze
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S858 - S859
[9] Efficacy and safety at 96 weeks of bulevirtide 2 mg or 10 mg monotherapy for chronic hepatitis D: results from an interim analysis of a phase 3 randomized study
Wedemeyer, Heiner
Aleman, Soo
Brunetto, Maurizia
Blank, Antje
Andreone, Pietro
Bogomolov, Pavel
Chulanov, Vladimir
Mamonova, Nina
Geyvandova, Natalia
Viacheslav, Morozov
Sagalova, Olga
Stepanova, Tatyana
Manuilov, Dmitry
Mercier, Renee-Claude
An, Qi
Flaherty, John F.
Osinusi, Anu
Lau, Audrey
Wiesch, Julian Schulze Zur
Cornberg, Markus
Zeuzem, Stefan
Lampertico, Pietro
JOURNAL OF HEPATOLOGY, 2023, 78 : S57 - S58
[10] Bulevirtide monotherapy at low and high doses in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study
Freismuth, A.
Wedemeyer, H.
Aleman, S.
Brunetto, M.
Black, A.
Andreone, P.
Bogomolov, P.
Chulanov, V.
Mamonova, N.
Geyvandova, N.
Morozov, V.
Sagalova, O.
Stepanova, T.
Manuilov, D.
Suri, V.
An, Qi
Flaherty, J. F.
Osinusi, A.
Zur Wiesch, J. Schulze
Cornberg, M.
Zeuzem, S.
Lampertico, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 52 - 53

← 1 2 3 4 5 →